Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Foto på Patrik Edén

Patrik Edén

Universitetslektor

Foto på Patrik Edén

Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy.

Författare

  • Emma Niméus
  • Cecilia Ritz
  • Patrik Edén
  • Anders Johnsson
  • Mattias Ohlsson
  • Carina Forsare
  • Gorel Östberg
  • Mårten Fernö
  • Carsten Peterson

Summary, in English

A large proportion of breast cancer patients are treated with adjuvant chemotherapy after the primary operation, but some will recur in spite of this treatment. In order to achieve an improved and more individualised therapy, our knowledge in mechanisms for drug resistance needs to be increased. We have investigated to what extent cDNA microarray measurements could distinguish the likelihood of recurrences after adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) treatment of premenopausal, lymph node positive breast cancer patients, and have also compared this with the corresponding performance when using conventional clinical variables. We tried several gene selection strategies, and built classifiers using the resulting gene lists. The best performing classifier with odds ratio (OR) = 6.5 (95% confidence interval (CI) = 1.4-62) did not outperform corresponding classifiers based on clinical variables. For the clinical variables, calibrated on the samples, either using all the clinical parameters or the Nottingham Prognostic Index (NPI) parameters, the areas under the receiver operating characteristics (ROC) curve were 0.78 and 0.79, respectively. The ORs at 90% sensitivity were 15 (95% CI = 3.1-140) and 10 (95% CI = 2.1-97), respectively. Our data have provided evidence for a comparable prediction of clinical outcome in CMF-treated breast cancer patients using conventional clinical variables and gene expression based markers. (c) 2006 Elsevier Ltd. All rights reserved.

Avdelning/ar

  • Bröstcancer-genetik
  • Beräkningsbiologi och biologisk fysik - Genomgår omorganisation
  • Bröstcancer Proteogenomik

Publiceringsår

2006

Språk

Engelska

Sidor

2729-2737

Publikation/Tidskrift/Serie

European Journal of Cancer

Volym

42

Issue

16

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Cancer and Oncology

Nyckelord

  • drug resistance
  • breast cancer
  • prognostic markers
  • cDNA microarray

Status

Published

Forskningsgrupp

  • Breast cancer Proteogenomics

ISBN/ISSN/Övrigt

  • ISSN: 1879-0852